At 8.4% CAGR, the Asia Pacific Intracranial pressure monitoring Devices Market is projected to be worth US$ 421.54 million by 2028, says The Business Market Insights

According to the Business Market Insights’ research, the Asia Pacific intracranial pressure monitoring devices market was valued at US$ 281.53 million in 2023 and is expected to reach US$ 421.54 million by 2028, registering a CAGR of 8.4% from 2023 to 2028. Increasing prevalence of neurological diseases and rising incidence of traumatic brain injuries (tbis) are the critical factors attributed to the Asia Pacific intracranial pressure monitoring devices market expansion. 

Many market players and researchers are developing new non-invasive ICP monitoring devices to expand their geographic reach and capacity to cater to many customers. In 2020, researchers developed a novel method for assessing intracranial pressure using non-invasive fundus images. The study focused on developing a novel, low-cost, fast, and easy measurement using noninvasive fundoscopy on non-dilated pupils to assess ICP using retinal A/V ratio. In this method, A/V-ratio decreased with ICP above 15 mmHg. The technique can potentially detect changes in ICP and possibly detect absolute ICP values. More research on this technique is needed to validate this.  The ICP waveform obtained noninvasively through this system has the potential to widen the applicability and understanding of ICP in less explored clinical fields. NIRS has several advantages over other noninvasive methods such as low cost, bedside compatibility for long-term and continuous monitoring, along with user independence. Thus, growing research on non-invasive ICP monitoring devices is likely to drive growth of the market during the forecast period.

On the contrary, limitations associated with ICP monitors hurdles the growth of Asia Pacific intracranial pressure monitoring devices market. 

Based on offering, the Asia Pacific intracranial pressure monitoring devices market is segmented into product & systems, solutions & platform, and services. The products and systems held 68.7% market share in 2023, amassing US$ 193.40million. It is projected to garner US$ 285.59 million by 2028 to expand at 8.1% CAGR during 2023–2028.

Based on type, the Asia Pacific intracranial pressure monitoring devices market is segmented into invasive and non-invasive. The invasive segment held 82.2% market share in 2023, amassing US$ 231.35 million. It is projected to garner US$ 343.25million by 2028 to expand at 8.2% CAGR during 2023–2028.

Based on applications, the Asia Pacific intracranial pressure monitoring devices market is segmented into traumatic brain injuries, reye’s syndrome, non-traumatic bleeds, hydrocephalus, space-occupying lesions, cerebral oedema, and others. The traumatic brain injuries held 36.4% market share in 2023, amassing US$ 102.46 million. It is projected to garner US$ 151.75 million by 2028 to expand at 8.2% CAGR during 2023–2028.

Based on end user, the Asia Pacific intracranial pressure monitoring devices market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held 59.3% market share in 2023, amassing US$ 167.00 million. It is projected to garner US$ 248.38 million by 2028 to expand at 8.3% CAGR during 2020–2028.

Based on country, the Asia Pacific intracranial pressure monitoring devices market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that the China captured 29.2% market share in 2023. It was assessed at US$ 82.21 million in 2023 and is likely to hit US$ 122.04 million by 2028, exhibiting a CAGR of 8.2% during the forecast period.  

Key players dominating the Asia Pacific intracranial pressure monitoring devices market are RAUMEDIC AG; Integra LifeSciences Holdings Corp; Medtronic Plc; and NovaSignal Corp among others.

• In Aug-2023, Integra LifeSciences announced an immediate global voluntary removal of its CereLink intracranial pressure monitors after receiving reports from some customers that their readings were out of range. The Princeton, N.J.-based, medical device manufacturer is investigating the problem.
• In Dec-2019, Raumedic launched a new home-use device, Raumed Home ICP, for monitoring intracranial pressure (ICP). The product was developed for patients suffering from hydrocephalus, a condition where excessive amounts of cerebrospinal fluid (CSF) accumulate in the brain. The device has recently received a CE marking.  

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com